Cargando…

Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study

BACKGROUND: Ofatumumab (OFA) is a fully human anti-CD20 monoclonal antibody administered with a 20 mg subcutaneous monthly dosing regimen. METHODS: Inclusion criteria were patients: 1) aged 18-55; 2) with a confirmed diagnosis of relapsing Multiple Sclerosis (RMS), per the revised 2010 McDonald crit...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Amico, Emanuele, Zanghì, Aurora, Fantozzi, Roberta, Centonze, Diego, Avolio, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2023
Materias:	Medicine, Neurology, Pharmacology, Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614110/ https://www.ncbi.nlm.nih.gov/pubmed/37534789 http://dx.doi.org/10.2174/1570159X21666230803161825

Ejemplares similares

Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications
por: Zanghì, Aurora, et al.
Publicado: (2022)

Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis
por: D’Amico, Emanuele, et al.
Publicado: (2022)

MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study
por: Zanghì, Aurora, et al.
Publicado: (2023)

Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study
por: D'Amico, Emanuele, et al.
Publicado: (2020)

Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience
por: Zanghì, Aurora, et al.
Publicado: (2020)

Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies
por: D'Amico, Emanuele, et al.
Publicado: (2021)

Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study
por: Zanghì, Aurora, et al.
Publicado: (2021)

The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis
por: D’Amico, Emanuele, et al.
Publicado: (2019)

Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort
por: D'Amico, Emanuele, et al.
Publicado: (2019)

Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
por: Kang, Connie, et al.
Publicado: (2021)

Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study
por: Zanghì, Aurora, et al.
Publicado: (2022)

First‐line therapies in late‐onset multiple sclerosis: An Italian registry study
por: Zanghì, Aurora, et al.
Publicado: (2021)

Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
por: Kang, Connie, et al.
Publicado: (2021)

Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing–Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study)
por: Centonze, Diego, et al.
Publicado: (2021)

Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience
por: Zanghì, Aurora, et al.
Publicado: (2020)

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
por: Bar-Or, Amit, et al.
Publicado: (2018)

Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis
por: Kramer, John, et al.
Publicado: (2023)

A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives
por: D’Amico, Emanuele, et al.
Publicado: (2016)

COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
por: Cross, Anne H., et al.
Publicado: (2022)

Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis
por: Yu, Huixin, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
por: Baharnoori, Moogeh, et al.
Publicado: (2022)

Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada
por: Bhan, Virender, et al.
Publicado: (2023)

Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
por: Cross, Anne H., et al.
Publicado: (2022)

Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab
por: Craner, Matthew, et al.
Publicado: (2022)

Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review
por: Ciancio, Alessia, et al.
Publicado: (2023)

Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis
por: D’Amico, Emanuele, et al.
Publicado: (2021)

Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension
por: Hauser, Stephen L, et al.
Publicado: (2023)

Theoretical and Therapeutic Implications of the Spasticity-Plus Syndrome Model in Multiple Sclerosis
por: Bruno, Antonio, et al.
Publicado: (2022)

Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Tuscano, Joseph, et al.
Publicado: (2020)

Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II
por: Gärtner, Jutta, et al.
Publicado: (2022)

Optimizing the “Time to pregnancy” in women with multiple sclerosis: the OPTIMUS Delphi survey
por: Carbone, Luigi, et al.
Publicado: (2023)

Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
por: Hauser, Stephen L, et al.
Publicado: (2022)

Pivotal Trials in Multiple Sclerosis: Similarities Prove Not to Be Useful
por: Avolio, Carlo, et al.
Publicado: (2021)

Inflammation and Corticospinal Functioning in Multiple Sclerosis: A TMS Perspective
por: Stampanoni Bassi, Mario, et al.
Publicado: (2020)

What Do We Know So Far about Ofatumumab for Relapsing Multiple Sclerosis? A Meta-Analytical Study
por: Taj, Hafiza Munazza, et al.
Publicado: (2022)

Immunocompetence after SARS-CoV-2 Infection in a Patient with Multiple Sclerosis Treated with Ofatumumab: A Case Report
por: Jasińska, Elżbieta
Publicado: (2022)

Autoimmune liver disease and multiple sclerosis: state of the art and future perspectives
por: Villani, Rosanna, et al.
Publicado: (2023)

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
por: D’Amico, Emanuele, et al.
Publicado: (2018)

An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
por: Saleem, Sidra, et al.
Publicado: (2019)

Effect of Seasonal Variation on Relapse Rate in Patients With Relapsing-Remitting Multiple Sclerosis in Saudi Arabia
por: Makkawi, Seraj, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7gm4mhaqftv5ar2p3liuhgcj96